Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert] July 27, 2020 “That is what I dream”: India’s journey to rolling out the... November 17, 2021 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Commemorating and Making History: The National Cancer Act 50th Anniversary February 8, 2021 Load more HOT NEWS Study Advances Fertility Preservation Approach for Male Cancer Survivors FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma Q&A: Learning About the Cancer Care Challenges LGBTQ+ People Face 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain...
